1. Stangelberger A, Schally AV, Rick FG, Varga JL, Baker B, Zarandi M, Halmos G. Inhibitory effects of antagonists of growth hormone releasing hormone on experimental prostate cancers are associated with upregulation of wild-type p53 and decrease in p21 and mutant p53 proteins. Prostate. 2011 Jul 27. doi: 10.1002/pros.21458. [Epub ahead of print]
2. Stangelberger A, Waldert M, Djavan B. Prostate cancer in elderly men. Rev Urol. 2008 Spring;10:111-9.
3. Margreiter M, Stangelberger A, Valimberti E, Herwig R, Djavan B. Biomarkers for early prostate cancer detection. Minerva Urol Nefrol. 2008;60:51-60. Review.
4. Stangelberger A, Schally AV, Djavan B. New treatment approaches for prostate cancer based on peptide analogues. Eur Urol. 2008;53:890-900. Review.
5. Stangelberger A, Schally AV, Zarandi M, Heinrich E, Groot K, Havt A, Kanashiro CA, Varga JL, Halmos G. The combination of antagonists of LHRH with antagonists of GHRH improves inhibition of androgen sensitive MDA-PCa-2b and LuCaP-35 prostate cancers. Prostate. 2007;67:1339-53.
6. Djavan B, Rocco B, Stangelberger A, De Cobelli O, Marberger M. Is the era of prostate-specific antigen over? BJU Int. 2007;100 Suppl 2:8-10. Review.
7. Stangelberger A, Schally AV, Varga JL, Zarandi M, Cai RZ, Baker B, Hammann BD, Armatis P, Kanashiro CA. Inhibition of human androgen-independent PC-3 and DU-145 prostate cancers by antagonists of bombesin and growth hormone releasing hormone  is linked to PKC, MAPK and c-jun intracellular signalling. Eur J Cancer. 2005;41:2735-44.
8. Stangelberger A, Schally AV, Nagy A, Szepeshazi K, Kanashiro CA, Halmos G. Inhibition of human experimental prostate cancers by a targeted cytotoxic luteinizing hormone-releasing hormone analog AN-207. Prostate. 2006;66:200-10.
9. Stangelberger A, Schally AV, Letsch M, Szepeshazi K, Nagy A, Halmos G, Kanashiro CA, Corey E, Vessella R. Targeted chemotherapy with cytotoxic bombesin analogue AN-215 inhibits growth of experimental human prostate cancers. Int J Cancer. 2006;118:222-9.
10. Stangelberger A, Schally AV, Varga JL, Hammann BD, Groot K, Halmos G, Cai RZ,  Zarandi M. Antagonists of growth hormone releasing hormone (GHRH) and of bombesin/gastrin releasing peptide (BN/GRP) suppress the expression of VEGF, bFGF, and receptors of the EGF/HER family in PC-3 and DU-145 human androgen-independent prostate cancers. Prostate. 2005;64:303-15.
11. Stangelberger A, Schally AV, Varga JL, Zarandi M, Szepeshazi K, Armatis P, Halmos G. Inhibitory effect of antagonists of bombesin and growth hormone-releasing hormone on orthotopic and intraosseous growth and invasiveness  of PC-3 human prostate cancer in nude mice. Clin Cancer Res. 2005;11:49-57.
12. Letsch M, Schally AV, Stangelberger A, Groot K, Varga JL. Antagonists of growth hormone-releasing hormone (GH-RH) enhance tumour growth inhibition induced by androgen deprivation in human MDA-Pca-2b prostate cancers. Eur J Cancer. 2004;40:436-44.

The Prostate
                                                                       Impact Factor:
The Prostate                                                           4.944
The International Journal of Cancer                             4.722
Clinical Cancer Research                                             7.338
European Journal of Cancer                                       4.944